What are the benefits to medical research and development including access to medicines and other healthcare innovations? We explore the views from the pharmaceutical industry and leading academics on what TTIP means for them. Submit your questions and join the discussion on September 11 4:00 PM CET 10:00 AM EDT

On November 25, 2014, the Economist is hosting a forum: The Global Crisis of Depression. This important, one-day event is sponsored by Lundbeck and will bring together policy-makers, academia, healthcare providers, patients, health industries and other stakeholders from around the world. According to the Economist, “Mental health, especially mood disorders such as depression, are increasingly society’s biggest long-term health issue.”

Sanofi is edging close to the fruition of a 20-year effort to develop the first effective vaccine against dengue fever, which hospitalises half a million people a year. Data from the first phase III trial of the vaccine have now been published in The Lancet and indicate that a three-dose course of the vaccine given to children aged two to 14 had an overall efficacy of 57 per cent against symptomatic dengue.

Online Q&A with Jeff Sturchio and Louis Galambos
June 10, 2014.  10:00am - 11:00am, EDT

Merck KGaA, Darmstadt, Germany, proposed the creation of a global alliance to help the World Health Organization (WHO) achieve its goal of eliminating schistosomiasis worldwide today in Geneva.

The innovative biopharmaceutical industry believes that a structured, collaborative effort to achieve universal health coverage can meet the shared goals of global health stakeholders of expanding patient access to quality medicines through innovative solutions and long-term sustainability of the health sector.

Novartis announced on Monday that it will partner with Malaria No More and the Power of One campaign to provide two million pediatric antimalarial treatments in Zambia.

“Although the incidence of malaria has decreased, the disease still kills a child every minute in Africa,” Novartis CEO Joseph Jimenez said. “Our commitment to Power of One reflects our company’s long-term efforts to fight malaria and Novartis remains dedicated to controlling and ultimately eliminating this deadly disease.”

Online Q&A with Eli Lilly’s John Lechleiter
April 2, 2014.  9:00am - 10:00am, EDT

Global Health Progress and the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) are proud to host an hour-long, conversation focused on the promise of medical innovation for global health with John C. Lechleiter - Chairman, President and CEO of Eli Lilly and President of IFPMA.

On April 2, the Uniting to Combat Neglected Tropical Diseases: A Conversation on Progress webcast and live Q&A will be broadcast from Institut Pasteur in Paris from 18:00 - 19:30 Central European Summer Time/12:00 - 13:30 Eastern Daylight Time. Panelists will address progress and challenges in the effort to control and eliminate 10 NTDs by 2020, with an overarching theme of how the unique alliance of pharmaceutical companies, development agencies, endemic countries, research organizations and private foundations has driven progress forward since the launch of the London Declaration on Neglected Tropical Diseases in 2012.

WHO South-East Asia Region, home to a quarter of the world’s population, was certified polio-free today by an independent commission under the WHO certification process. This is the fourth of six WHO Regions to be certified, marking an important step towards global polio eradication. With this step, 80% of the world’s population now lives in certified polio-free regions.